Chain Pharmacy

Many cite PBM fees as the primary cause in NCPA survey.

The deal is now official, but the companies have been acting as one for some time.

Patients at-risk for substance abuse more easily identified and managed.

First new treatment of its kind in over 20 years.

Characterized by severe abdominal pain.

The DEA had access to information about where opioids were being sold, but didn’t act on it. Why?

Biosimilars may need more time to devleop in the market.

For granulomatosis with microscopic polyangiitis in children.

Now approved for risk reductions in patients with type 2 diabetes mellitus.

Racemic substitutions for single-enantiomer drugs offer new opportunities for savings.

Biologic medicines could lower spending by $153 billion by 2023.

Several pharmacy groups appealed guideline revisions.

Will be part of the U.S.’s public health emergency medical supplies and pharmaceuticals.

Online pharmacy that discovered the impurity discontinues sales.

Monoclonal antibody for autoimmune and neurodegenerative disorders.

An estimated 100 million Americans lack good access to pharmacies.

Caused by lower income, insurance status, higher prices, poor transportation, long distances.

Now approved in 7mg and 14 mg tablets.

Layoffs highlight increasing jobs problem. 

Monoclonal antibody shows potential for lupus nephritis treatment.

Programs shown to improve patient outcomes, reduce antibiotic resistance, and decrease healthcare costs.

23,600 cases across 29 states since 2016.

Fear, one's faith in the government, and likelihood of exposure are leading factors.

Oncologists recognize the potential of artificial intelligence (AI) in improving the quality of care and patient outcomes according to new research.